13.1 Sterile, Nonsterile & Hazardous Compounding

13.1 Sterile, Nonsterile & Hazardous Compounding

Quick Answer: USP <795> = nonsterile compounding; USP <797> = sterile compounding (compounded sterile preparations, CSPs); USP <800> = hazardous-drug handling to protect workers, patients, and the environment. Illinois 68 Ill. Adm. Code 1330.640 requires pharmacies that compound to follow official USP-NF compounding standards for sterile and nonsterile work and adds Illinois operational rules (patient-specific dispensing, office-use limits, equipment, records, sterile add-on inspection, PIC training documentation). Distinguish traditional compounding (§503A) from outsourcing facilities (§503B) and commercial manufacturing. Hazardous-drug items test NIOSH list awareness, PPE, containment, storage, and disposal—NABP 4.2.3 and 4.5.

Compounding is not “mixing powders until it looks right.” On the Illinois MPJE it is a regulated professional activity under pharmacy practice law, USP standards, and federal drug law. Area 4 (Pharmacy Operations)—about 21% of the exam—explicitly includes storage, hazardous drugs, and compounding. This section builds the national practice framework; Section 13.2 layers beyond-use dates (BUDs), Illinois 1330.640 operational detail, labeling, ingredient sources, and 503A vs 503B.

Why Compounding Appears on a Jurisprudence Exam

You are not expected to design a cleanroom from memory, but you are expected to know:

1. Which standard governs the activity (nonsterile vs sterile vs hazardous)
2. Whether the activity is lawful compounding versus manufacturing/outsourcing
3. Who may compound and under what training/supervision
4. What documentation proves the process was controlled
5. How Illinois Part 1330 and IDFPR enforce facility readiness

When a stem describes cream for one patient with an allergy to a commercial excipient, think <795> + patient-specific 503A. When it describes chemotherapy IV prep, think <797> + <800> containment. When it describes shipping sterile stock to dozens of clinics without patient names, think 503B / wholesale / manufacturing risk—not ordinary retail compounding.

USP Chapters at Exam Depth

Teaching shortcuts that save points:

• <795> ≠ sterile. Capsules and ointments are classic nonsterile examples.
• <797> ≠ “hospital only.” Any pharmacy that compounds sterile preparations must meet sterile standards.
• <800> is not a BUD table. It is an exposure-control standard. A drug can be both a CSP under <797> and a hazardous drug under <800> (e.g., many antineoplastics).

Nonsterile compounding essentials (<795>)

Exam-safe nonsterile themes:

• Designated area used for compounding (Illinois also requires an exclusive compounding area under 1330.640(e))
• Personnel competency for the dosage forms prepared
• Component selection from quality sources; do not use ingredients of unknown quality
• Equipment accurate for the scale of weighing/measuring (Illinois: scales/measuring devices with sufficient accuracy)
• Process controls to prevent mix-ups and cross-contamination
• Master formulation record and compounding record (see documentation section below)
• Beyond-use date assigned using chapter framework and any stability data (Section 13.2)

Sterile compounding essentials (<797>)

Exam-safe sterile themes:

• Primary engineering controls (PECs) providing ISO Class 5 air in the direct compounding area (e.g., laminar airflow workbench, biological safety cabinet, compounding aseptic isolator—device type depends on product and hazard status)
• Secondary engineering controls (buffer/ante areas) for cleanroom suites; segregated compounding area (SCA) models for limited Category 1-type work with shorter BUDs
• Garbing and hand hygiene order and discipline
• Aseptic technique and first-air protection
• CSP categories (commonly tested as Category 1 shorter BUDs vs Category 2/3 longer BUDs with stricter facility/process requirements—know the framework; do not invent unpublished hour tables beyond commonly tested anchors)
• Environmental monitoring / cleaning as quality systems, not optional “nice to haves”
• Immediate-use concepts for emergent situations (tight time and process limits—never a loophole for routine batching)

Hazardous drugs (<800> + competency 4.2.3)

NABP 4.2.3 (hazardous drugs) rewards candidates who can map a vignette to risk controls, not candidates who only know the chapter number.

Hazardous-drug handling stack:

1. Identify HDs using the current NIOSH list (and facility HD list/assessment of risk where the chapter permits limited alternative controls for some dosage forms)
2. Receive and unpack with procedures that limit exposure (designated areas; PPE as policy requires)
3. Store to prevent contamination of non-HD inventory—commonly separate storage; antineoplastics and drugs requiring manipulation often need negative pressure / externally vented storage concepts under <800>
4. Compound hazardous sterile products in appropriate containment PECs (e.g., Class II BSC or CACI); nonsterile HD compounding uses containment ventilated enclosures when required
5. PPE: double gloves (chemotherapy-rated when indicated), gown, eye protection, and respiratory protection when aerosols/splashes or other exposure risks exist—match PPE to the task, not to fashion
6. Transport and administer with closed-system transfer devices (CSTDs) when required by standard/policy for antineoplastics
7. Dispose of HD waste per facility policy and environmental rules; never “regular trash for convenience”
8. Spill kits, training, and medical surveillance programs as organizational controls

Exam vignette pattern: “Tech crushes a hazardous tablet on an open counter next to counting trays used for other patients’ meds.” Correct analysis: wrong location, wrong engineering controls, cross-contamination risk, PPE/training failure—not “it’s only a tablet so <800> does not apply.”

Illinois note on <800>: 1330.640 adopts official USP compounding standards for sterile and nonsterile compounding and states an exception regarding USP Chapter <800> as it pertains to hazardous-drug handling in healthcare settings. That means you should not invent that every <800> detail is automatically “codified as Illinois Part 1330 text.” You should still master <800> concepts for NABP hazardous-drug competencies, workplace safety expectations, and any vignette that tests safe HD practice. When Illinois and federal/practice standards both apply, use the more protective operational control that lawfully governs the setting.

Compounding vs Manufacturing; Patient-Specific vs Anticipatory

Federal architecture (high level)

Illinois operational echo (1330.640): A pharmacy may generally dispense compounded drugs pursuant to a valid patient-specific prescription, except as the Section allows (limited nonsterile office use, veterinary office use, and pathways that require 503B + wholesale distributor compliance for sterile office use).

Anticipatory compounding: Preparing limited quantities before a prescription arrives, based on routine, readily observed dispensing patterns, can be lawful when tied to pharmacy practice—not when it becomes de facto manufacturing for open distribution. Illinois 1330.640(e)(10) restricts sales of compounded drugs to other pharmacies not under common ownership, or to clinics/hospitals/manufacturers, except limited pathways (office-use subsection, centralized prescription filling under Section 25.5 of the Act, including anticipatory compounding tied to routine patterns).

Office use (Illinois definitions in 1330.640):

• Office use = practitioner administration of a non-patient-specific compounded drug in office/facility settings
• Delivering a compound to a prescriber’s office pursuant to a valid patient-specific prescription is not “office use” under the definition
• Sterile compounding for office use is prohibited unless the pharmacy is in full compliance with 21 U.S.C. § 353b (503B), including registration as an outsourcing facility and licensure as a wholesale drug distributor under the Wholesale Drug Distribution Licensing Act
• Limited nonsterile office-use dispensing is allowed under quantity, record, and “For Office Use Only – Not for Resale” labeling rules (detailed in Section 13.2)

Trap: “Our sterile cleanroom is beautiful, so we can sell bags of CSPs to any clinic as stock.” False for ordinary 503A pharmacies under Illinois 1330.640(c).

Illinois Pharmacies: USP + IDFPR Rules Together

68 Ill. Adm. Code 1330.640 (Pharmaceutical Compounding Standards) is the Illinois spine. Core messages:

1. Strength/quality/purity must not differ from official USP-NF standards for named preparations (Section 25 of the Act language incorporated into the rule).
2. Sterile and nonsterile pharmaceutical compounding standards are governed by the official USP-NF Compounding Compendium edition referenced in the rule (candidates should answer with current official USP chapters, not outdated memorized editions).
3. Equipment and environmental minimums: separate storage for compounding materials; accurate scales/devices; area used exclusively for compounding; consumables appropriate to services; current USP Compounding Compendium available (electronic/subscription acceptable).
4. Logbook/record system tracking each compounded drug with component lot numbers, component expirations, and BUD—for each nonsterile compound and each sterile compound with BUD > 24 hours.
5. PIC ongoing duty: ensure pharmacists, student pharmacists, registered certified technicians, and registered technicians who compound are adequately trained for the type of compounding performed; documentation of training maintained at all times (1330.640(h)).
6. Adding sterile compounding after initial licensure: pharmacy must be inspected and the compounding area approved by the Department; PIC notifies the Department and arranges inspection (1330.640(i)).
7. Sterile compounding pharmacies need additional reference texts (compatibility references, extended stability files), 24-hour pharmacist accessibility with phone on labels for off-site use, and emergency-medication readiness for certain off-site/home infusion models (1330.640(f)).

Former standalone sterile rule 1330.670 is repealed—do not hunt for a separate “old sterile only” section as current law; sterile requirements live in 1330.640 plus USP <797>.

Documentation: Master Formulation Records & Compounding Records

USP practice and Illinois record rules converge on a dual-document model candidates must name correctly:

Illinois additionally requires patient profile/medication record elements for compounded sterile drugs and a five-year, readily retrievable audit trail including purchase records and patient profiles (1330.640(e)(8)). Labels must carry BUD (and time if appropriate) and the special statement that the prescription was specifically compounded for the patient at the direction of the prescriber (Section 13.2).

Exam habit: If a stem says the pharmacy “just rewrites the label from last month’s vial,” you are looking at a documentation and BUD control failure, not a minor clerical shortcut.

Personnel, Training & Competency

Compounding is not unrestricted tech work and not free-form pharmacist improvisation:

• Only trained personnel participate; training matches sterile vs nonsterile vs hazardous risks
• Pharmacist supervision and final professional responsibility remain—technicians do not “own” clinical release decisions
• Media-fill / gloved fingertip style competencies are classic sterile training anchors under <797> frameworks (know that competency assessment exists; exact frequencies can be chapter-specific—do not invent numbers if the stem does not give them)
• Hazardous-drug handlers need HD-specific training before independent work
• PIC is the Illinois accountability anchor for training documentation (1330.640(h)) and for ensuring the compounding service matches the licensed facility’s approved operations

Worked Vignettes

Vignette A — Wrong chapter. Pharmacy prepares preservative-free ophthalmic drops in a non-ISO counter space used for counting tablets. Failure: sterile product under <797> controls, not casual nonsterile technique.

Vignette B — Hazardous crush. Staff splits hazardous tablets with a shared counting tray, no double gloves or containment. Failure: HD identification, PPE, containment, and cross-contamination controls (<800> / 4.2.3).

Vignette C — Sterile office stock. Community pharmacy sells non-patient-specific sterile bags to a medical spa as “office use” without 503B/wholesale credentials. Violation of 1330.640(c).

Vignette D — New sterile service. PIC starts sterile compounding after remodeling without Department inspection/approval of the compounding area. Violation of 1330.640(i).

Vignette E — No MFR/CR. Staff compounds a complex cream from memory; no master formula, no batch record, no component lots. Failure of USP documentation expectations and Illinois logbook requirements.

Study Checklist

1. Map activity → <795> / <797> / <800> (and combinations).
2. Map business model → 503A patient-specific vs 503B outsourcing vs manufacturing.
3. Memorize Illinois patient-specific default, sterile office-use ban without 503B+wholesale path, and PIC training/inspection duties in 1330.640.
4. Hazardous drugs: identify → store → contain → PPE → dispose.
5. Documentation: MFR (recipe) + CR (batch) + lots/expirations + BUD.
6. Adding sterile services requires IDFPR inspection/approval—not a silent menu add-on.

Section 13.2 turns these standards into BUDs, Illinois operational labeling/records detail, ingredient-source expectations, and inspection readiness for compounding areas.